These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26886466)

  • 21. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCSK9 inhibitors and managing cost in the managed care setting.
    Stadler SL; Cook TJ
    Am J Manag Care; 2017 Jun; 23(9 Suppl):S149-S155. PubMed ID: 28978220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
    Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ
    BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
    Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
    J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alirocumab for the treatment of hypercholesterolemia.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Biol Ther; 2017 May; 17(5):633-643. PubMed ID: 28277798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.
    Strat AL; Ghiciuc CM; Lupuşoru CE; Mitu F
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):228-32. PubMed ID: 27483697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach.
    Scherer N; Dings C; Böhm M; Laufs U; Lehr T
    J Clin Pharmacol; 2017 Jul; 57(7):846-854. PubMed ID: 28263403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PCSK9 inhibitors and dyslipidemias: an update on clinical evidence].
    Norata GD
    G Ital Cardiol (Rome); 2014 May; 15(5):301-5. PubMed ID: 25002170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
    Patel RS; Scopelliti EM; Savelloni J
    Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.
    Dahagam C; Goud A; Abdelqader A; Hendrani A; Feinstein MJ; Qamar A; Joshi PH; Swiger KJ; Byrne K; Quispe R; Jones SR; Blumenthal RS; Martin SS
    Future Cardiol; 2016 Mar; 12(2):139-48. PubMed ID: 26911578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of evolocumab and its potential in the treatment of hyperlipidemia.
    Cicero AF; Colletti A; Borghi C
    Drug Des Devel Ther; 2015; 9():3073-82. PubMed ID: 26109850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids.
    Shantha GP; Robinson JG
    Clin Pharmacol Ther; 2016 Jan; 99(1):59-71. PubMed ID: 26492546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
    Smith L; Mosley J; Yates J; Caswell L
    J Pharm Pharm Sci; 2016; 19(1):137-46. PubMed ID: 27096698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
    Farnier M
    Curr Opin Lipidol; 2016 Dec; 27(6):597-604. PubMed ID: 27755114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.